Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pandemic Impact Limited As Chugai Reports Strong First Half

But Outlook More Uncertain

Executive Summary

Roche’s Japanese affiliate says the impact of the pandemic on its second quarter was limited, but points to a more uncertain outlook for the rest of the year, during which it vows to keep focusing on innovation.

You may also be interested in...



Coronavirus Update: Roche's Actemra Fails In Phase III COVID Study

Disappointment as Roche/Chugai antibody tocilizumab misses most endpoints. 

Roche’s First Anti-TIGIT Data Support Dual Checkpoint Inhibition Strategy

Tiragolumab plus Tecentriq increased response rates versus Tecentriq alone in a Phase II study, with the greatest benefit in PD-L1-high NSCLC. The combination regimen already is being test in Phase III.

Coronavirus Update: Rapid Japan Approval For Remdesivir, Combination With Lilly's Olumiant Is Next Hope

Plus: Chugai enters into Singapore research alliance, Korean consortium reports vaccine progress.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC142686

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel